5 results about "Orally active" patented technology

The present invention relates to the field of pharmaceutical compositions suitable for the oral administration of an active in animals. In particular, the present invention relates to a liquid drug-containing formulation and to the use thereof. The present invention further relates to the use of a liquid formulation aid composition comprising at least one natural oil of herbal origin in a liquid drug-containing formulation for improving the acceptance or voluntary acceptance of drug intake in animal.

The invention provides an antibacterial peptide as well as application, a product and a preparation method thereof, and relates to the technical field of biology. The invention screens out a novel antibacterial peptide from kidney beans, which can specifically kill escherichia coli O157: H7 without damaging intestinal flora. By designing protective peptide chains at two ends of an effective sequence, an innovative strategy for keeping oral activity without embedding is established, and the stability and the utilization efficiency are remarkably improved. Meanwhile, a plant-based transgenic expression system is constructed, high-purity production of the antibacterial peptide is realized, and the antibacterial peptide can be directly applied to oral administration.

The invention discloses an application of bacteria in preparation of a synergist for an immune checkpoint inhibitor. The bacteria are active bacteria or inactive whole-cell gut microbiota. By using a monobacterial oral preparation of human endogenous gut microbiota Alistipes combined with an immune checkpoint inhibitor, an anti-tumor immune protective response and an effect of remodeling gut microbiota is generated by stimulation of oral administration of active human commensal gut microbiota or inactive whole-cell human commensal gut microbiota, which significantly enhances an efficacy of the immune checkpoint inhibitor on multiple tumor species, enhances anti-tumor immune function, is conducive to improving the response rate of cancer immunotherapy populations, and has better safety, prolongs overall survival time of cancer patients, expands cancer patient population benefited from cancer immunotherapy (immunotherapy checkpoint inhibitors), provides new combination therapy regimens and therapeutic drugs to treat immune checkpoint inhibitor-refractory tumor patients, and expands the patient benefited from cancer immunotherapy.

The application belongs to the technical field of medicine, and particularly relates to application of trifluperidol in treatment of cerebrovascular diseases. Trifluperidol is a D1 / D2 dopamine receptor antagonist with oral activity and a novel PI3K inhibitor, and trifluperidol has anti-proliferative activity on cancer cells and induces apoptosis. The application discloses trifluperidol for the first time, and no report is found on effective treatment of trifluperidol against ischemic stroke, especially the application creatively proposes that trifluperidol significantly reduces the volume of acute cerebral infarction of a mouse with focal cerebral ischemia, which indicates that trifluperidol can be used for treating ischemic stroke.

An orally active, brain penetrant first-in-class small molecule midkine inhibitor for use in the treatment of triple-negative breast cancer, brain tumors (including glioblastoma, medulloblastoma, and NF1-mutant optic pathway gliomas), ovarian and endometrial cancers, lung cancer, as well as gynecologic non-malignant conditions such as endometriosis, uterine fibroids, and preterm birth, in which tumor cells and / or pathological cells exhibit heightened midkine signaling and express multiple midkine receptors.